I’d like to formally request that Vibrant Wellness create an optional, reduced-cost add-on that pairs the Salivary Hormone profile with the Hormone Zoomer (urinary metabolites)—similar to the way the Essential Fatty Acid profile can be tacked on to the Micronutrient test at a substantial discount.

Why the combination matters

Clinical completeness.

Saliva captures free, bio-available levels and is uniquely reliable for titrating topical/transdermal therapies, preventing inadvertent overdosing.

Urine supplies the metabolite picture—phase-I and phase-II estrogen, androgen, and cortisol pathways—that saliva alone cannot provide.

Together they give me the most accurate dosing and safety data, especially when I’m managing patients on topical or oral bio-identical HRT.

Better outcomes & higher provider confidence. In my practice, patients whose treatment is guided by both matrices reach symptom control faster and require fewer follow-up adjustments.

Affordability drives adoption. Many of my patients already purchase bundled packages (3-test bundle $700 / 5-test bundle $1,050). When the saliva + urine pair has to occupy two bundle slots, cost becomes a barrier. Pricing the pair as a single discounted add-on—outside the bundle count—would

keep total out-of-pocket costs comparable to your current single-panel prices,

free up bundle slots for additional Vibrant tests (Oxidative Stress, Environmental Toxins, etc.), and

ultimately increase overall test volume.

Precedent exists. The Micronutrient panel already allows a heavily discounted Essential Fatty Acid add-on. A parallel structure for hormone testing would be easy for clinicians to understand and promote.

Proposed structure

Panel Current solo price Bundle slot(s) used

Salivary Hormone $ X – 1

Hormone Zoomer $ Y – 1

Saliva + Zoomer (new) – $ ≈ Y + (0.5 × X) 1

*example pricing only; I’m happy to discuss specifics.

I’m convinced this change would increase test utilization, improve patient affordability, and highlight Vibrant’s commitment to clinically meaningful innovation.

Please let me know what additional information you need. I’d be glad to pilot the combined panel and share anonymized outcome data.

From Richard Aballay, MD